Stability issues of parenteral chemotherapy drugs

Journal of Oncology Pharmacy Practice

Volumn 13, Issue 1, 2007, Pages 27-31

  de Lemos, Mário L ^a   Hamata, Linda ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Antineoplastic agents; Drug compounding; Drug stability; Drug storage

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG PRESERVATIVE; FLUOROURACIL; VINCRISTINE;

ARTICLE; CONSENSUS; CONTINUOUS INFUSION; DRUG CONTAMINATION; DRUG DECOMPOSITION; DRUG FORMULATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG INFUSION; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUROTOXICITY; PHARMACIST; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTUM CANCER; SYRINGE;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG CONTAMINATION; DRUG INDUSTRY; DRUG LABELING; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; INFUSIONS, INTRAVENOUS; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; SYRINGES;

EID: 34250176936     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155206075236     Document Type: Article

References (16)

1. National Institute for Occupational Safety and Health (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; 25 March 2004: 71-83.
2. CSHP Task Force to Develop Guidelines for Sterile Product Compounding. Information Paper: Guidelines for preparation of sterile products in pharmacies. Ottawa, Ontario: Canadian Society of Hospital Pharmacists, 2001 Official Publications; 1996.
3. Kastango ES. The ASHP discussion guide for compounding sterile preparations. American Society of Health-System Pharmacists, Inc., 2004: 5.
4. United States Pharmacopeia (USP). (1191) Stability considerations in dispensing practice. USP 26-NF 21. Rockville, Maryland: UPS Convention, Inc., 2003: 2414.
5. United States Pharmacopeia (USP). C795) Pharmacy compounding. USP 26-NF 21. Rockville, Maryland: UPS Convention, Inc., 2003: 2198.
6. United States Pharmacopeia (USP). (1206) sterile drug products for home use. USP 26-NF 21. Rockville, Maryland: UPS Convention, Inc., 2003: 2417-8, 526-7.
7. United States Pharmacopeia (USP). (341) Antimicrobial agents. USP 26-NF 21. Rockville, Maryland: UPS Convention, Inc., 2003: 2064-5.
8. United States Pharmacopeia (USP). (797) Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: UPS Convention, Inc., 2004: 2369.
9. Trissel L. Personal communication. Director, Clinical Pharmaceutics Research, University of Texas M. D. Anderson Cancer Center. 23 February 2005.
10. Walker S. Personal communication. Coordinator, Quality Control & Research, Department of Pharmacy, Sunnybrook & Women's Health Sciences Centre, Toronto. 23 February 2005.
11. B.C. Cancer Agency Provincial Pharmacy Professional Practice Council. Council meeting minutes. Vancouver, British Columbia: BC Cancer Agency; 26 October 2005.
12. B.C. Cancer Agency - Vancouver Cancer Centre. Site Directive VIII-A-60: Expiry of vials after puncture. Vancouver, British Columbia: BC Cancer Agency; 17 April 1991.
13. Pharmaceutical preservative. National Library of Medicine - Medical Subject Headings MeSH Descriptor Data. 2004. Available from http://wwwnlmnihgov/mesh/MBrowserhtml. Accessed 14 June, 2004.
14. Dunkelman H, Earl HM, Twelves C. Acute reversible neurological deficit following intrathecal chemotherapy. Cancer Chemother Pharmacol 1991; 27: 329-30.
15. Trissel LA. Handbook on injectable drugs, thirteenth edition. American Society of Health-System Pharmacists Inc., 2005.
16. Stiles ML, Allen LV Jr, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy 1989; 46: 2036-40.